Trial Profile
A Multicenter, Non-randomized, Open-label Dose Escalation Phase Ib Study of Regorafenib in Combination With Pembrolizumab in Patients With Advanced Hepatocellular Carcinoma (HCC) With no Prior Systemic Therapy
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Sep 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Regorafenib (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Sponsors Bayer
- 14 Sep 2022 Status changed from active, no longer recruiting to completed.
- 13 May 2022 Planned End Date changed from 7 Oct 2022 to 26 Sep 2022.
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology